155 related articles for article (PubMed ID: 37285798)
1. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.
Achini-Gutzwiller FR; Schilham MW; von Asmuth EGJ; Jansen-Hoogendijk AM; Jol-van der Zijde CM; van Tol MJD; Bredius RGM; Güngör T; Lankester AC; Moes DJAR
Blood Adv; 2023 Aug; 7(16):4462-4474. PubMed ID: 37285798
[TBL] [Abstract][Full Text] [Related]
2. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
[TBL] [Abstract][Full Text] [Related]
3. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
4. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.
Willemsen L; Jol-van der Zijde CM; Admiraal R; Putter H; Jansen-Hoogendijk AM; Ostaijen-Ten Dam MM; Wijnen JT; van Kesteren C; Waaijer JL; Lankester AC; Bredius RG; van Tol MJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):473-82. PubMed ID: 25485863
[TBL] [Abstract][Full Text] [Related]
5. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
[TBL] [Abstract][Full Text] [Related]
6. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.
Grimaldi F; Potter V; Perez-Abellan P; Veluchamy JP; Atif M; Grain R; Sen M; Best S; Lea N; Rice C; Pagliuca A; Mufti GJ; Marsh JCW; Barber LD
Biol Blood Marrow Transplant; 2017 Feb; 23(2):293-299. PubMed ID: 27816648
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract][Full Text] [Related]
8. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):635-641. PubMed ID: 28089878
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
10. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
Loeff FC; van Egmond EHM; Moes DJAR; Wijnands C; Von Dem Borne PA; Veelken H; Falkenburg JHF; Jedema I; Halkes CJM
Transpl Immunol; 2019 Dec; 57():101209. PubMed ID: 31207283
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.
Admiraal R; Jol-van der Zijde CM; Furtado Silva JM; Knibbe CAJ; Lankester AC; Boelens JJ; Hale G; Etuk A; Wilson M; Adams S; Veys P; van Kesteren C; Bredius RGM
Clin Pharmacokinet; 2019 Dec; 58(12):1609-1620. PubMed ID: 31131436
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
[TBL] [Abstract][Full Text] [Related]
14. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.
Admiraal R; Nierkens S; Bierings MB; Bredius RGM; van Vliet I; Jiang Y; Lopez-Yurda M; Versluijs AB; Zwaan CM; Lindemans CA; Boelens JJ
Lancet Haematol; 2022 Feb; 9(2):e111-e120. PubMed ID: 35114150
[TBL] [Abstract][Full Text] [Related]
15. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
Kanda Y; Oshima K; Kako S; Fukuda T; Uchida N; Miyamura K; Kondo Y; Nakao S; Nagafuji K; Miyamoto T; Kurokawa M; Okoshi Y; Chiba S; Ohashi Y; Takaue Y; Taniguchi S
Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
[TBL] [Abstract][Full Text] [Related]
16. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
17. CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen.
Woelfinger P; Epp K; Schaefer L; Kriege D; Theobald M; Bopp T; Wagner-Drouet EM
Br J Haematol; 2020 Oct; 191(2):253-262. PubMed ID: 32410220
[TBL] [Abstract][Full Text] [Related]
18. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease.
Yanir AD; Hanson IC; Shearer WT; Noroski LM; Forbes LR; Seeborg FO; Nicholas S; Chinn I; Orange JS; Rider NL; Leung KS; Naik S; Carrum G; Sasa G; Hegde M; Omer BA; Ahmed N; Allen CE; Khaled Y; Wu MF; Liu H; Gottschalk SM; Heslop HE; Brenner MK; Krance RA; Martinez CA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1643-1650. PubMed ID: 29630926
[TBL] [Abstract][Full Text] [Related]
19. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
20. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
